https://www.europesays.com/3273278/ European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease #Adrenoleukodystrophy #Agonist #brain #Europe #Gadolinium #NeurodegenerativeDisease #Therapeutics #therapy
